Scholarlink

Background <p>The prevalence of neurodegenerative diseases (NDDs) is escalating, and complex medication regimens lead to a high incidence of drug-related problems (DRPs). This study analyzes DRPs in this population to identify their incidence and causes. The findings aim to provide a theoretical basis for clinical intervention strategies and outpatient pharmacy monitoring, ultimately ensuring rational drug use and enhancing patient safety.</p> Method <p>This study was conducted among patients with neurodegenerative diseases at a major hospital in Shanghai, China, between July 2023 and June 2024. The Pharmaceutical Care Network Europe (PCNE) classification system version 9.1 was used to identify DRPs. Data was entered and analyzed using SPSS software. Full model and stepwise logistic regression analyses were used to identify predictors of DRP occurrence in the total sample and Alzheimer’s disease (AD)/Parkinson’s disease (PD) subgroups. Outpatient medications were summarized. A p-value of less than 0.05 was considered statistically significant.</p> Result <p>A total of 254 patients (90 AD, 171 PD) were involved, resulting in 398 DRPs. The most commonly encountered type of DRP was treatment effectiveness (48.99%), and drug selection (46.73%) was the most common cause. The majority of clinical pharmacist interventions were provided at the drug level (98.99%), primarily involving dose adjustment and usage method adjustment. The acceptance level of interventions by prescribers was high (90.70%), with the acceptance rate in AD patients (92.96%) being higher than that in PD patients (90.07%). Through pharmacist intervention, over 70% of DRPs were completely resolved. Anti-Parkinson’s disease drugs, antianxiety or antidepressant drugs, and sedatives and hypnotics were the three main drug classes contributing to DRPs. Lifestyle habits (smoking, drinking), the number of comorbidities, and the dose of medication were factors associated with the development of DRPs.</p> Conclusion <p>This study finding revealed that DRPs were prevalent in patients with PD and AD. Medication care was a protective factor, whereas polypharmacy and the presence of multiple comorbidities were significantly associated with an elevated risk of DRPs. Based on the PCNE classification and the “PCIAO” process, clinical pharmacists’ involvement in precision management offers a robust evidence base and provides clear guidance for optimizing therapeutic regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Classifying drug-related problems of neurodegenerative diseases in the physician-pharmacist joint clinic of neurology: an application of the PCNE method

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月3日

查看全文
  • Yuanjun Tang,
  • Runjuan Yang,
  • Meina Zhang,
  • Chunyan Zhou,
  • Ming Chen,
  • Hui Pan,
  • Yingyi Qin,
  • Yaxing Gui,
  • Guorong Fan

摘要

Background

The prevalence of neurodegenerative diseases (NDDs) is escalating, and complex medication regimens lead to a high incidence of drug-related problems (DRPs). This study analyzes DRPs in this population to identify their incidence and causes. The findings aim to provide a theoretical basis for clinical intervention strategies and outpatient pharmacy monitoring, ultimately ensuring rational drug use and enhancing patient safety.

Method

This study was conducted among patients with neurodegenerative diseases at a major hospital in Shanghai, China, between July 2023 and June 2024. The Pharmaceutical Care Network Europe (PCNE) classification system version 9.1 was used to identify DRPs. Data was entered and analyzed using SPSS software. Full model and stepwise logistic regression analyses were used to identify predictors of DRP occurrence in the total sample and Alzheimer’s disease (AD)/Parkinson’s disease (PD) subgroups. Outpatient medications were summarized. A p-value of less than 0.05 was considered statistically significant.

Result

A total of 254 patients (90 AD, 171 PD) were involved, resulting in 398 DRPs. The most commonly encountered type of DRP was treatment effectiveness (48.99%), and drug selection (46.73%) was the most common cause. The majority of clinical pharmacist interventions were provided at the drug level (98.99%), primarily involving dose adjustment and usage method adjustment. The acceptance level of interventions by prescribers was high (90.70%), with the acceptance rate in AD patients (92.96%) being higher than that in PD patients (90.07%). Through pharmacist intervention, over 70% of DRPs were completely resolved. Anti-Parkinson’s disease drugs, antianxiety or antidepressant drugs, and sedatives and hypnotics were the three main drug classes contributing to DRPs. Lifestyle habits (smoking, drinking), the number of comorbidities, and the dose of medication were factors associated with the development of DRPs.

Conclusion

This study finding revealed that DRPs were prevalent in patients with PD and AD. Medication care was a protective factor, whereas polypharmacy and the presence of multiple comorbidities were significantly associated with an elevated risk of DRPs. Based on the PCNE classification and the “PCIAO” process, clinical pharmacists’ involvement in precision management offers a robust evidence base and provides clear guidance for optimizing therapeutic regimens.